** Analysts at Morningstar raise fair value estimate on Australia's Polynovo Ltd PNV.AX by 5% to A$1.15
** Medical devices maker Polynovo, on Tuesday, recorded its highest ever monthly sales of A$10.1 mln ($6.3 mln) in November
** Company logged total group revenue of A$49.6 mln till November, up 25.5% vs the same period last year
** Fiscal 2025 revenue forecast of A$136 mln ($84.95 mln) implies 32% growth on last year as we anticipate a stronger-second half on favourable currency movements and continued market share gains - Morningstar
** Six of eight analysts rate the stock "buy" or higher, two "hold"; their median PT is A$2.77, according to data compiled by LSEG
** PNV stock down 24.5% YTD, as of the last close
($1 = 1.6010 Australian dollars)
(Reporting by Roshan Thomas in Bengaluru)
((Roshan.Thomas@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。